Clinically, IL-6 and IL-6 receptor antibodies have proven to have great efficacy in conditions that are driven by IL-6 such as rheumatoid arthritis [77], systemic juvenile arthritis [78] and Castleman’s disease [79]. This evidence concerns the gene IL6 and Castleman disease.